^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DS-M1

    i
    Other names: DS-M1
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo
    Drug class:
    Menin-MLL inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Development and characterization of a novel orally bioavailable menin-MLL inhibitor for treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation (AACR 2021)
    These data indicate that DS-M1 has a high potency as an antitumor drug with the potential to provide survival advantage in acute leukemia patients with MLL-r and NPM1-mu. Currently, a Phase 1/2 clinical study of DS-M1 is planned in AML and ALL patients with MLL-r or NPM1-mu.
    Clinical • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • HOXA9 (Homeobox A9) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MEIS1 (Meis Homeobox 1)
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CD14 expression • MLL fusion
    |
    DS-M1